Teicoplanin: an alternative drug for the treatment of COVID-19?
Editorial
[키워드] acute respiratory syndrome
antibiotic
appear
China
conserved
coronavirus
COVID-19
Drug repurposing
Efficacy
Efficiency
first stage
human cells
in vitro
infections
inhibit
lack
MERS-CoV
Middle East
Novel coronavirus
Outbreaks
Patient
Pneumonia
Potential treatment
Remdesivir
respiratory syndrome coronavirus
ribavirin
Ritonavir
SARS-CoV-2
shown
specific treatment
Spread
staphylococcal
Teicoplanin
the epidemic
therapeutic
Transmission
treat
Treatment
viral life cycle
virus
Wuhan
[DOI] 10.1016/j.ijantimicag.2020.105944 [Article Type] Editorial
[DOI] 10.1016/j.ijantimicag.2020.105944 [Article Type] Editorial